Eurobio-Scientific SA(FR:ALERS)
€26.350.00 (0.00%)
FR:ALERS
Eurobio-Scientific SA financials statements
€26.35
At close:0.00 (0.00%)
Want to see FR:ALERS full AI Analyst Report?
Eurobio-Scientific SA (ALERS) Ratios
1 Followers
Eurobio-Scientific SA Ratios
FR:ALERS's free cash flow for Q2 2026 was €3.29M. For the 2026 fiscal year, FR:ALERS's free cash flow was decreased by €-3.55M and operating cash flow was €6.85M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.98 | 2.03 | 2.72 | 2.59 | 4.79 |
| Quick Ratio | 1.36 | 1.42 | 2.32 | 2.21 | 4.34 |
| Cash Ratio | 0.44 | 0.49 | 0.93 | 0.83 | 2.57 |
| Solvency Ratio | 0.30 | 0.16 | 0.13 | 0.22 | 1.40 |
| Operating Cash Flow Ratio | 0.41 | 0.38 | 0.51 | 0.73 | 1.81 |
| Short-Term Operating Cash Flow Coverage | 8.40 | 23.04 | 2.02 | 3.05 | 17.81 |
| Net Current Asset Value | € 18.75M | € 11.27M | € 2.75M | € -9.38M | € 123.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.13 | 0.32 | 0.34 | 0.07 |
| Debt-to-Equity Ratio | 0.09 | 0.19 | 0.57 | 0.66 | 0.10 |
| Debt-to-Capital Ratio | 0.08 | 0.16 | 0.36 | 0.40 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.04 | 0.13 | 0.32 | 0.35 | 0.04 |
| Financial Leverage Ratio | 1.40 | 1.44 | 1.81 | 1.92 | 1.31 |
| Debt Service Coverage Ratio | 6.94 | 2.86 | 1.27 | 2.38 | 16.67 |
| Interest Coverage Ratio | 7.73 | 2.39 | 2.29 | 23.97 | 158.21 |
| Debt to Market Cap | 0.04 | 0.11 | 0.52 | 0.52 | 0.04 |
| Interest Debt Per Share | 1.76 | 3.87 | 9.42 | 11.24 | 1.49 |
| Net Debt to EBITDA | -0.13 | 0.60 | 2.09 | 1.63 | -0.97 |
| Profitability Margins | |||||
| Gross Profit Margin | 40.47% | 46.44% | 44.00% | 42.62% | 52.75% |
| EBIT Margin | 9.14% | 7.74% | 8.68% | 20.29% | 38.85% |
| EBITDA Margin | 19.17% | 13.17% | 18.79% | 26.53% | 43.11% |
| Operating Profit Margin | 9.14% | 8.65% | 7.76% | 20.23% | 38.97% |
| Pretax Profit Margin | 4.62% | 4.07% | 5.34% | 19.45% | 38.61% |
| Net Profit Margin | 2.88% | 2.58% | 3.70% | 16.34% | 32.78% |
| Continuous Operations Profit Margin | 2.88% | 2.58% | 3.70% | 16.34% | 32.78% |
| Net Income Per EBT | 62.37% | 63.49% | 69.30% | 84.01% | 84.90% |
| EBT Per EBIT | 50.48% | 47.01% | 68.80% | 96.16% | 99.06% |
| Return on Assets (ROA) | 1.89% | 1.56% | 1.53% | 7.55% | 28.94% |
| Return on Equity (ROE) | 2.65% | 2.24% | 2.76% | 14.47% | 37.86% |
| Return on Capital Employed (ROCE) | 7.34% | 6.29% | 3.85% | 11.30% | 41.58% |
| Return on Invested Capital (ROIC) | 4.48% | 3.94% | 2.52% | 8.99% | 34.27% |
| Return on Tangible Assets | 4.62% | 3.86% | 2.96% | 41.82% | 35.77% |
| Earnings Yield | 1.95% | 1.55% | 2.64% | 11.98% | 20.73% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.47 | 4.67 | 4.14 | 3.81 | 3.95 |
| Payables Turnover | 4.82 | 5.42 | 5.62 | 4.73 | 12.53 |
| Inventory Turnover | 3.51 | 3.08 | 3.41 | 4.04 | 5.36 |
| Fixed Asset Turnover | 13.38 | 12.14 | 10.62 | 12.05 | 18.38 |
| Asset Turnover | 0.66 | 0.60 | 0.41 | 0.46 | 0.88 |
| Working Capital Turnover Ratio | 3.72 | 2.27 | 1.43 | 1.34 | 1.65 |
| Cash Conversion Cycle | 109.84 | 129.10 | 130.25 | 108.89 | 131.38 |
| Days of Sales Outstanding | 81.69 | 78.11 | 88.15 | 95.88 | 92.38 |
| Days of Inventory Outstanding | 103.88 | 118.38 | 107.01 | 90.26 | 68.14 |
| Days of Payables Outstanding | 75.73 | 67.38 | 64.91 | 77.25 | 29.14 |
| Operating Cycle | 185.57 | 196.48 | 195.16 | 186.14 | 160.52 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.84 | 1.63 | 2.40 | 4.09 | 6.03 |
| Free Cash Flow Per Share | 0.61 | 1.31 | 2.04 | 3.82 | 5.86 |
| Dividend Paid and CapEx Coverage Ratio | 1.50 | 5.13 | 6.60 | 14.77 | 35.44 |
| Capital Expenditure Coverage Ratio | 1.50 | 5.13 | 6.60 | 14.77 | 35.44 |
| Operating Cash Flow Coverage Ratio | 1.18 | 0.49 | 0.27 | 0.37 | 4.18 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.11 | 0.20 | 0.27 | 0.35 |
| Free Cash Flow Yield | 2.52% | 5.20% | 12.39% | 18.74% | 21.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 51.81 | 64.69 | 37.92 | 8.35 | 4.82 |
| Price-to-Sales (P/S) Ratio | 1.48 | 1.67 | 1.40 | 1.36 | 1.58 |
| Price-to-Book (P/B) Ratio | 1.36 | 1.45 | 1.05 | 1.21 | 1.83 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 39.72 | 19.24 | 8.07 | 5.34 | 4.59 |
| Price-to-Operating Cash Flow Ratio | 13.24 | 15.49 | 6.85 | 4.97 | 4.46 |
| Price-to-Earnings Growth (PEG) Ratio | 2.53 | -6.95 | -0.47 | -0.14 | -0.32 |
| Enterprise Value Multiple | 7.57 | 13.29 | 9.56 | 6.77 | 2.70 |
| Enterprise Value | 245.26M | 271.06M | 234.72M | 274.28M | 214.78M |
| EV to EBITDA | 7.57 | 13.29 | 9.56 | 6.77 | 2.70 |
| EV to Sales | 1.45 | 1.75 | 1.80 | 1.80 | 1.16 |
| EV to Free Cash Flow | 39.04 | 20.16 | 10.33 | 7.03 | 3.38 |
| EV to Operating Cash Flow | 13.01 | 16.23 | 8.77 | 6.55 | 3.28 |
| Tangible Book Value Per Share | 3.16 | 2.47 | 1.98 | -9.60 | 11.09 |
| Shareholders’ Equity Per Share | 17.95 | 17.45 | 15.71 | 16.86 | 14.74 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.38 | 0.37 | 0.31 | 0.16 | 0.15 |
| Revenue Per Share | 16.49 | 15.12 | 11.71 | 14.93 | 17.03 |
| Net Income Per Share | 0.47 | 0.39 | 0.43 | 2.44 | 5.58 |
| Tax Burden | 0.62 | 0.63 | 0.69 | 0.84 | 0.85 |
| Interest Burden | 0.50 | 0.53 | 0.62 | 0.96 | 0.99 |
| Research & Development to Revenue | 0.03 | 0.03 | 0.07 | 0.02 | 0.02 |
| SG&A to Revenue | 0.31 | 0.29 | 0.11 | 0.07 | 0.04 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 3.88 | 4.18 | 5.54 | 1.68 | 1.08 |
Currency in EUR
